Nektar Therapeutics (NAS:NKTR)
$ 1.02 0.01 (0.99%) Market Cap: 186.30 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.74 GF Score: 56/100

Nektar Therapeutics Investor and Analyst Call at SITC Transcript

Nov 12, 2021 / 05:00PM GMT
Release Date Price: $13.36 (-1.40%)
Operator

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics SITC conference call.

(Operator Instructions)

Please be advised that today's conference may be recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Vivian Wu from the IR team.

Vivian Wu

Thank you, Crystal. Good afternoon, everyone, and thank you for joining us on today's analyst call to review data presented for Nektar's immuno-oncology pipeline at the 2021 Society of Immunotherapy for Cancer meeting.

Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's drug candidate, NKTR-255 and other potential drug candidates. Clinical trial results, the timing of the startup and plans for ongoing planned clinical trials with partners, the therapeutic potential of our drug candidates, the timing and outcome of regulatory decisions and future availability of clinical trial data. Because these statements relate to the future, they are subject to inherent uncertainties and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot